Compare Abeona Therapeutics Inc (ABEO) vs Tempus AI (TEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Tempus AI — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Tempus AI trades at $56.91 (market cap $10.79B). The key difference: Tempus AI is far larger — about 28.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals.
| ABEO | TEM | |
|---|---|---|
Market Cap | $373.32M | $10.79B |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $103.25 |
52-Week Low | $4.17 | $42.37 |
Enterprise Value | $228.22M | $11.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Tempus AI (TEM) trades at $60.70, up 0.71% with a bullish technical signal. The stock shows strong analyst support with 8 buy ratings and a $63.50 consensus target, though fundamentals reveal challenges with a -22.2% net margin and -$245M net loss for 2025. Recent FDA approvals and AI platform expansions drive positive sentiment, while cash flow remains dependent on financing activities.
Outlook remains cautiously optimistic given TEM's unique AI healthcare data platform and expanding partnerships, but investors face significant execution risks amid persistent losses. The stock's 7.85 P/S ratio reflects growth expectations, yet profitability concerns and high cash burn require careful monitoring for sustainable turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
